Slingshot members are tracking this event:
Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Jul 25, 2016
- What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma? CELG Execute By: Aug 31, 2016
Related Keywords Remarc Study, Revlimid, Diffuse Large B-cell Lymphoma, R-chop Therapy, Lymphoma Study Association, Chop Chemotherapy, Rituximab